Jove
Visualize
Contáctanos
JoVE
x logofacebook logolinkedin logoyoutube logo
ACERCA DE JoVE
Visión GeneralLiderazgoBlogCentro de Ayuda JoVE
AUTORES
Proceso de PublicaciónConsejo EditorialAlcance y PolíticasRevisión por ParesPreguntas FrecuentesEnviar
BIBLIOTECARIOS
TestimoniosSuscripcionesAccesoRecursosConsejo Asesor de BibliotecasPreguntas Frecuentes
INVESTIGACIÓN
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchivo
EDUCACIÓN
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualCentro de Recursos para ProfesoresSitio de Profesores
Términos y Condiciones de Uso
Política de Privacidad
Políticas

Videos de Conceptos Relacionados

Acute Respiratory Failure-III01:30

Acute Respiratory Failure-III

1.3K
Hypercapnic respiratory failure, also known as Type 2 or ventilatory respiratory failure, is a severe condition characterized by the body's inability to effectively remove carbon dioxide (CO2) from the bloodstream. It leads to an arterial CO2 pressure (PaCO2) exceeding 45 mmHg and a blood pH above 7.35. This situation indicates that the body's ventilatory demand, or the ventilation needed to maintain normal PaCO2 levels, surpasses its supply or the maximum gas flow achievable without...
1.3K
Acute Respiratory Failure-V01:29

Acute Respiratory Failure-V

775
The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
775
Pneumothorax-I01:26

Pneumothorax-I

2.2K
A pneumothorax is a condition where air builds up in the space between the lung and the chest wall, causing the lung to collapse. This condition arises when air enters the space between the parietal and visceral pleura, disrupting the negative pressure essential for lung inflation. This can lead to a partial or complete collapse of the lung.
Pneumothorax can be even further classified as spontaneous, traumatic, and tension pneumothorax.
2.2K
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

528
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
528
Cellular Injury I: Introduction01:00

Cellular Injury I: Introduction

95
Cellular injury occurs when a cell cannot maintain homeostasis or adapt to stressors such as hypoxia, toxins, or trauma. Depending on severity and duration, injury may be reversible, allowing recovery, or irreversible, leading to cell death.General Mechanisms of Cell InjuryAlthough causes vary, most cellular injuries arise from a few key mechanisms that disrupt essential functions and often amplify one another. Cell survival depends on the extent and balance of these disturbances.ATP depletion...
95
Cellular Injury IV: Necrosis01:16

Cellular Injury IV: Necrosis

97
Necrosis is a form of irreversible cell death caused by severe injury such as ischemia, toxins, or trauma. Unlike programmed cell death, it is an uncontrolled, pathological process that typically provokes inflammation in surrounding tissues.Pathophysiologic ChangesNecrosis begins when cells sustain critical damage, leading to swelling of organelles, particularly mitochondria, and rapid ATP depletion. As energy levels decline, membrane ion pumps fail, leading to calcium influx and eventually,...
97

También podría leer

Artículos Relacionados

Artículos vinculados a este trabajo por autores compartidos, revista y gráfico de citas.

Ordenar por
Same author

Integrated Proteomic and scRNA-Seq Analysis Reveals Pyroptosis-Related Subtypes in Lung Adenocarcinoma.

The clinical respiratory journal·2026
Same author

Associations Between a Surrogate Index of Insulin Resistance and Hyperuricemia in Young and Middle-Aged Patients With Type 2 Diabetes Mellitus.

Journal of diabetes research·2026
Same author

An inhaled AK0705 modulates PI3K/AKT/MAPK/NF-κB signaling to alleviate LPS-NETs-induced inflammation and pyroptosis in acute lung injury.

International immunopharmacology·2026
Same author

Integrated platform for EV separation and controlled release based on gelatin microspheres for diabetic wound treatment.

Regenerative biomaterials·2026
Same author

PmTCP18, a class I TCP transcription factor from Prunus mume, regulates plant height and branching when ectopically expressed in poplar.

Plant physiology and biochemistry : PPB·2026
Same author

Quantitative analysis and clinical evaluation of 20- and 22-kDa growth hormone isoforms in somatotroph adenoma using immunocapture coupled with LC-MS/MS.

Clinical chemistry and laboratory medicine·2026

Video Experimental Relacionado

Updated: May 7, 2026

Isolation of Pulmonary Artery Smooth Muscle Cells from Neonatal Mice
08:02

Isolation of Pulmonary Artery Smooth Muscle Cells from Neonatal Mice

Published on: October 19, 2013

18.5K

PARK7 objetivo: el 4-fenilbutirato de sodio protege las células endoteliales del estrés oxidativo y la piroptosis

Jian Xu1, Tianchang Wei1, Yuhan Wang2

  • 1Shanghai Key Laboratory of Lung Inflammation and Injury, Shanghai Respiratory Research Institute, Department of Pulmonary Medicine, Zhongshan Hospital, Fudan University, Shanghai 200032, China.

International immunopharmacology
|August 20, 2025
PubMed
Resumen

El 4-fenilbutirato de sodio (Na-PBA) protege contra la lesión pulmonar aguda (ALI) al reducir la piroptosis de las células endoteliales. Este efecto protector se basa en la proteína PARK7, que ofrece una nueva estrategia terapéutica para las enfermedades pulmonares.

Palabras clave:
Lesión pulmonar agudaCélula endotelialEl PARK7La piroptosisEl 4-fenilbutirato de sodio

Más Videos Relacionados

Method of Direct Segmental Intra-hepatic Delivery Using a Rat Liver Hilar Clamp Model
09:22

Method of Direct Segmental Intra-hepatic Delivery Using a Rat Liver Hilar Clamp Model

Published on: April 2, 2017

14.2K
Inducing Acute Lung Injury in Mice by Direct Intratracheal Lipopolysaccharide Instillation
11:07

Inducing Acute Lung Injury in Mice by Direct Intratracheal Lipopolysaccharide Instillation

Published on: July 6, 2019

25.4K

Videos de Experimentos Relacionados

Last Updated: May 7, 2026

Isolation of Pulmonary Artery Smooth Muscle Cells from Neonatal Mice
08:02

Isolation of Pulmonary Artery Smooth Muscle Cells from Neonatal Mice

Published on: October 19, 2013

18.5K
Method of Direct Segmental Intra-hepatic Delivery Using a Rat Liver Hilar Clamp Model
09:22

Method of Direct Segmental Intra-hepatic Delivery Using a Rat Liver Hilar Clamp Model

Published on: April 2, 2017

14.2K
Inducing Acute Lung Injury in Mice by Direct Intratracheal Lipopolysaccharide Instillation
11:07

Inducing Acute Lung Injury in Mice by Direct Intratracheal Lipopolysaccharide Instillation

Published on: July 6, 2019

25.4K

Área de la Ciencia:

  • Biología celular
  • La medicina molecular
  • Medicina de los pulmones

Sus antecedentes:

  • Los mecanismos de lesión de las células endoteliales en la lesión pulmonar aguda (ALI) no se comprenden completamente.
  • Los tratamientos efectivos dirigidos a las células endoteliales en la ILA son limitados.
  • El 4-fenilbutirato de sodio (Na-PBA), un inhibidor de la histona deacetilasa, muestra potencial para reducir el daño oxidativo, pero su papel en la piroptosis endotelial y su relación con PARK7 no están claros.

Objetivo del estudio:

  • Investigar los efectos del Na-PBA en la piroptosis de las células endoteliales y el estrés oxidativo en un modelo de ratón con IAL inducida por lipopolisacáridos (LPS).
  • Aclarar los mecanismos moleculares subyacentes a los efectos protectores del Na-PBA, centrándose en el papel de PARK7.
  • Evaluar el Na-PBA como un agente terapéutico potencial para la ALI.

Principales métodos:

  • Se estableció un modelo de IAL inducida por lipopolisacáridos (LPS) en ratones y se utilizaron células endotelial de la vena umbilical humana (HUVEC) in vitro.
  • Se administró Na-PBA para evaluar su impacto en el daño del tejido pulmonar, los marcadores inflamatorios y la piroptosis endotelial.
  • Se empleó la secuenciación de ARN, la inmunoblotación, la eliminación de genes y la sobreexpresión para explorar las vías moleculares, incluida la vía del citocromo c (Cyt c) -caspasa9-caspasa3-GSDME y el papel de PARK7 y NRF2.

Principales resultados:

  • El pretratamiento con Na-PBA alivió la lesión pulmonar, redujo el edema pulmonar y disminuyó las citoquinas inflamatorias en ratones LPS-ALI.
  • El Na-PBA redujo significativamente el estrés oxidativo y la piroptosis de las células endoteliales a través de la vía Cyt c-caspase9-caspase3-GSDME, tanto in vivo como in vitro.
  • El Na-PBA aumentó la expresión de PARK7, y sus efectos protectores fueron dependientes de PARK7 en las células endoteliales, mitigando la ALI.

Conclusiones:

  • El Na-PBA alivia la ALI mediante la modulación del estrés oxidativo y la piroptosis a través de una vía dependiente de PARK7 que involucra a Cyt c, caspase9, caspase3 y GSDME.
  • El Na-PBA aumenta la regulación de PARK7 a través de la inhibición de la histona deacetilasa (HDAC), potencialmente amplificada por el NRF2, que estabiliza las mitocondrias e inhibe la fuga del citocromo c.
  • Este estudio identifica una nueva estrategia terapéutica dirigida a la lesión de las células endoteliales en enfermedades pulmonares mediante la modulación de la vía mediada por PARK7.